News
-
-
-
-
-
-
-
-
PRESS RELEASE
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
Heidelberg Pharma granted orphan drug designation by FDA for its ATAC candidate HDP-101, targeting multiple myeloma. The designation provides significant benefits for the development and potential marketing of the drug -
-
PRESS RELEASE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
Heidelberg Pharma AG announces financial figures and successful business performance in 2023, including efficacy data from HDP-101 clinical trial. New Management Board team and expansion of ADC technology platform
-
Allied Universal Event Services Professional Winner of Golden State Warriors’ Champion Spotlight Annual Starting 5
-
Viking Capital Announces Closing of Latest 252 Unit Acquisition in Austin - San Antonio Corridor
-
Assays Confirm High-Grade Tarcoola Open Pit Extensions
-
Seismic Survey Reveals Tarcoola Goldfield Architecture
-
OTCQB Trading Secured with DTCC Registration Approval
-
Turkiye Garanti Bankasi A.S.: Prospectus – Summary
-
Turkiye Garanti Bankasi A.S.: Prospectus – Capital Markets Instrument Note
-
EQS-Adhoc: United Internet AG: Non-scheduled, non-cash impairment on Tele Columbus investment
-
Shelly Group: Successful placement of shares with participation of BIT Capital for targeted increase in free float
-
Extraordinary General Meeting of 12 June 2024 - All proposals of the Board of Directors were confirmed by the General Meeting
-
Monthly disclosure of the total number of shares and voting rights - 31/05/2024
-
Combined General Meeting, June 13, 2024
-
Europorte and Kerlink revolutionize freight by launching Track Value, the first logistics application using Kinéis IoT space connectivity
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2024
-
Declaration of voting rights at the end of May 2024